ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

  • Authors:
    • Jing Zhao
    • Juntian Liu
    • Nan Wu
    • Hailian Zhang
    • Shichao Zhang
    • Lijuan Li
    • Meng Wang
  • View Affiliations

  • Published online on: June 24, 2020     https://doi.org/10.3892/ol.2020.11768
  • Pages: 2499-2505
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to analyze the expression levels of angiopoietin‑like 4 (ANGPTL4) in breast cancer to investigate the association between ANGPTL4 and breast cancer. Immunohistochemistry was performed on formalin‑fixed paraffin‑embedded tissues, including 205 invasive ductal carcinoma (IDC) of no special type, 40 normal breast, 40 atypical ductal hyperplasia (ADH) and 40 ductal carcinomas in situ (DCIS) tissues. The non‑parametric Kruskal‑Wallis test was used to evaluate the differential expression of ANGPTL4 and clinicopathological parameters in breast cancer. Kaplan‑Meier analysis and Cox regression analysis were used to evaluate the association between the expression levels of ANGPTL4 and the prognosis of breast cancer. The results revealed that ANGPTL4 expression was higher in IDC (63.4%; 130/205) compared with in normal breast tissues (17.5%; 7/40), ADH (30%; 12/40) and DCIS (37.5%; 15/40). The clinical significance of ANGPTL4 expression was analyzed in a total of 205 IDC tissues, and high expression levels of ANGPTL4 were positively associated with pathological stage (P<0.001), tumor size (P<0.001), histological grade (P<0.001), lymph node metastasis (P<0.001), distant metastasis (P<0.001) and local recurrence (P<0.001). Kaplan‑Meier analysis revealed that patients with high ANGPTL4 expression had a shorter overall survival (OS; P<0.001) and disease‑free survival (DFS; P<0.001) compared with patients with low ANGPTL4 expression. Multivariate Cox regression analysis revealed that ANGPTL4 was an independent prognostic factor for breast cancer OS (P=0.034) and DFS (P=0.011). The results of the present study demonstrated that ANGPLT4 was associated with malignant progression and poor prognosis of breast cancer, suggesting that ANGPLT4 may be a novel therapeutic target for breast cancer.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao J, Liu J, Wu N, Zhang H, Zhang S, Li L and Wang M: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer. Oncol Lett 20: 2499-2505, 2020
APA
Zhao, J., Liu, J., Wu, N., Zhang, H., Zhang, S., Li, L., & Wang, M. (2020). ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer. Oncology Letters, 20, 2499-2505. https://doi.org/10.3892/ol.2020.11768
MLA
Zhao, J., Liu, J., Wu, N., Zhang, H., Zhang, S., Li, L., Wang, M."ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer". Oncology Letters 20.3 (2020): 2499-2505.
Chicago
Zhao, J., Liu, J., Wu, N., Zhang, H., Zhang, S., Li, L., Wang, M."ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer". Oncology Letters 20, no. 3 (2020): 2499-2505. https://doi.org/10.3892/ol.2020.11768